wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities

Pasoglou, Vasiliki; Michoux, Nicolas; Tombal, Bertrand; Jamar, François; Lecouvet, Frédéric

doi:10.1007/s40336-015-0120-4

Cited by 15 publications

(27 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…"Interobserver agreement for reading of WB--MRI images including DWI has been tested in detail in a small patient cohort and shown to be 0.98 (0.89--0.99) and 0.97 (0.83--0.99) for median and mean global apparent diffusion coefficient (ADC) respectively 45 . In other studies, whole body MRI has outperformed BS (K = 0.87 [0.66; 1.00] for ADC, K = 0.60 [0.26; 0.78 for BS)" 46,47 . The variability of ADC measurements is <15%, making it sensitive to treatment--induced changes, so that response is quantifiable and measurable 48,49,50 .…”

Section: Modern Imaging Methods (Mims) (mentioning

confidence: 96%

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Lecouvet

Oprea-Lager

Liu

et al. 2018

The Lancet Oncology

Self Cite

105

View full text Add to dashboard Cite

Oligometastatic disease (OMD) represents a clinical and anatomical manifestation between localized and polymetastatic disease. In prostate cancer, as with other cancers, recognition of OMD enables focal, metastases-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and may delay further metastatic progression, thus increasing overall survival. To validate their efficacy, metastases-directed therapies require imaging methods that definitively recognize OMD and reliably monitor response, particularly to avoid morbidity of inappropriately treating disease subsequently recognized as polymetastatic. This paper reviews current imaging methods used for identifying metastatic prostate cancer at first diagnosis, at biochemical recurrence (BCR), or at the castration resistant stage. Standard imaging methods recommended by current guidelines have insufficient diagnostic accuracy for reliably diagnosing OMD. Modern imaging methods using positron emission tomography /computed tomography (PET/CT) with tumour specific radiotracers (choline or PSMA ligand), and increasingly even whole-body magnetic resonance imaging (WB-MRI) with diffusion-weighted imaging (DWI), allow earlier and more precise identification of metastases. The EORTC Imaging Group suggests clinical algorithms for integrating modern imaging methods into the care pathway at the various stages of prostate cancer in order to identify OMD. Clinical trials utilizing modern imaging methods are proposed for evaluating the benefits of metastasis-directed therapies.

show abstract

Section: Modern Imaging Methods (Mims) (mentioning

confidence: 96%

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Lecouvet

Oprea-Lager

Liu

et al. 2018

The Lancet Oncology

Self Cite

105

View full text Add to dashboard Cite

show abstract

“…In recent years, the PET-like technique, magnetic resonance systemic diffusion-weighted imaging (WB-DWI), has a very high sensitivity to malignant tumor examination, and can obtain system-specific tumor imaging similar to PET. Inspection costs are much lower than PET and are widely used in clinical practice [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…With the development of new MRI scanners and coil technology, whole-body diffusion-weighted imaging (WB-DWI) with background body signal suppression, has been recognized as a new imaging modality for the assessment of metastases of various malignancies. MRI has high value in the identification of benign and malignant lesions of the bone [ 7 , 8 ]. Due to the strong magnetic field of MRI, the examination of patients with metal implants is limited [ 9 ], except for WB-DWI, the other MRI techniques can not complete one-time whole body bone imaging compared with bone scan.…”

Section: Introductionmentioning

confidence: 99%

MRI and bone scintigraphy for breast cancer bone metastase: a meta-analysis

2019

View full text Add to dashboard Cite

AbstractObjectiveThe aim of this study was to compare the diagnostic value of magnetic resonance image (MRI) and bone scintigraphy (BS) in the diagnosis of breast cancer bone metastases.MethodsSearching in the databases including PubMed, Embase about the comparative study of MRI and bone scintigraphy in the diagnosis of breast cancer bone metastases during 2000~2018. After we screened further, the extracted effective data were calculated by Meta-Disc 1.4 software.ResultsWe obtained 4 articles. The pooled estimates for sensitivity of MRI, BS were 0.99 (95% CI, [0.95, 1.00]) and 0.93 (95% CI, [0.88, 0.97]) respectively; For specificity were 0.99 (95% CI, [0.95, 1.00]) and 0.86 (95% CI, [0.79, 0.92]) respectively. The AUC of SROC curve for MRI and BS were 0.9948 and 0.9675 respectively.ConclusionMRI remains to be a satisfactory method for the diagnosis of breast cancer bone metastases and should first be considered for patients.

show abstract

“…Regarding WB-MRI, even though various studies demonstrated its superiority compared to the current staging methods, there is an important heterogeneity between different countries, centers, or even teams, regarding the anatomic sequences, acquisition planes and duration of the examination [ 42 ]. Thus, there is an urgent need for precision and standardization of the protocols, depending on the cancer type and the patient.…”

Section: Limitations Of Current Staging Methodsmentioning

confidence: 99%

Optimising TNM Staging of Patients with Prostate Cancer Using WB-MRI

Pasoglou¹,

Michoux²,

Tombal³

et al. 2016

Journal of the Belgian Society of Radiology

Self Cite

View full text Add to dashboard Cite

Multiparametric Magnetic Resonance Imaging (mp-MRI) is the current standard of reference for the local staging of prostate cancer (PCa). On the other hand, despite the low sensitivity and specificity of Technetium Bone Scanning (BS) for the detection of bone metastases (BM) and of Body Computed Tomography CT for the detection of lymph node metastases (LNM), these techniques are routinely used, in the current clinical practice. Nevertheless, whole Body MRI (WB-MRI) and Positron Emission Tomography Computed Tomography (PET-CT) are emerging as robust tools for the staging of oncologic patients, including those with (PCa).The available techniques (BS, WB-MRI, PET, CT) for the detection of BM in oncologic patients were compared and showed striking center differences in terms of anatomic sequences and planes used. This heterogeneity and the long acquisition time of WB-MRI protocols – due to the addition of multiple anatomic sequences in different planes – questioned whether a single three dimensional (3D) sequence could replace the multiple anatomic sequences used for node and bone staging of PCa. We demonstrated that WB-MRI is a credible tool for the detection of bone and node metastasis.The second question addressed the possibility to obtain a complete TNM staging of PCa in a single MRI session. A WB-MRI protocol was developed to enable complete, T (local), N (regional) and M (distant) staging of PCa in a single session, in less than an hour. This ‘all-in-one’ protocol proved to be as efficient as the sum of exams currently in use for the staging of PCa (ie: mp-MRI of the prostate for ‘T’ staging, Thoraco-abdominal CT for ‘N’ staging and bone scintigraphy for ‘M’ staging).

show abstract

wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities

Cited by 15 publications

References 75 publications

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

MRI and bone scintigraphy for breast cancer bone metastase: a meta-analysis

Optimising TNM Staging of Patients with Prostate Cancer Using WB-MRI

Contact Info

Product

Resources

About